Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

Lucia B. Jilaveanu; Fengmin Zhao; Christopher R. Zito; John M. Kirkwood; Katherine L. Nathanson; Kurt D'Andrea; Melissa Wilson; David L. Rimm; Keith T. Flaherty; Sandra J. Lee; Harriet M. Kluger

doi:10.1371/journal.pone.0069748

Loading metrics

Open Access

Peer-reviewed

Research Article

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

Lucia B. Jilaveanu,

Affiliation Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America
⨯
Fengmin Zhao,

Affiliation Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
⨯
Christopher R. Zito,

Affiliations Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America, Department of Biology, School of Health and Natural Sciences, University of Saint Joseph, West Hartford, Connecticut, United States of America
⨯
John M. Kirkwood,

Affiliation Pittsburgh Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
⨯
Katherine L. Nathanson,

Affiliation Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
⨯
Kurt D'Andrea,

Affiliation Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
⨯
Melissa Wilson,

Affiliation Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
⨯
David L. Rimm,

Affiliation Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America
⨯
Keith T. Flaherty,

Affiliations Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America
⨯
Sandra J. Lee,

Affiliation Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
⨯
Harriet M. Kluger

* E-mail: Harriet.Kluger@yale.edu

Affiliation Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America
⨯

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

Lucia B. Jilaveanu,
Fengmin Zhao,
Christopher R. Zito,
John M. Kirkwood,
Katherine L. Nathanson,
Kurt D'Andrea,
Melissa Wilson,
David L. Rimm,
Keith T. Flaherty,
Sandra J. Lee

Published: August 6, 2013
https://doi.org/10.1371/journal.pone.0069748

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Melanoma
Is the Subject Area "Melanoma" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Biomarkers
Is the Subject Area "Biomarkers" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
MAPK signaling cascades
Is the Subject Area "MAPK signaling cascades" applicable to this article?

Thanks for your feedback.
Hepatocellular carcinoma
Is the Subject Area "Hepatocellular carcinoma" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Cancer chemotherapy
Is the Subject Area "Cancer chemotherapy" applicable to this article?

Thanks for your feedback.